{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:52Z","timestamp":1790794852853,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stricturing Crohn\u2019s disease (CD) represents a major cause of morbidity, with limited prospective data addressing response to treatment. We performed a systematic review to evaluate the efficacy of biologic and small-molecule therapies in stricturing CD and to assess the role of imaging modalities in diagnosing and monitoring bowel stenoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, Scopus, and Web of Science through August 26, 2025. Prospective studies, including randomized controlled trials and prospective observational cohorts, reporting outcomes in adult patients with stricturing CD treated with biologics or small molecules were included. Risk of bias was assessed using the RoB 2 and ROBINS-I tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 22\u200a306 records identified, 7 publications corresponding to 10 prospective studies (6 randomized controlled trials, 4 nonrandomized studies) were included. All studies evaluated biologic therapies, predominantly anti-tumor necrosis factor agents; no prospective trials specifically assessed small-molecule therapies in stricturing CD. Due to methodological heterogeneity, a meta-analysis was not appropriate. Across studies, biologic therapy was associated with clinical improvement and, in selected cohorts, reductions in inflammatory activity and need for surgery. Response appeared to vary according to stricture severity, with lower rates in nonpassable lesions. Intestinal ultrasonography and magnetic resonance were investigated in 4 studies, showing reductions in bowel wall thickness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prospective evidence for medical therapy in stricturing CD is limited and restricted to anti-tumor necrosis factor \u03b1 agents. Imaging plays an important role in characterization and monitoring but lacks a standardized fibrosis assessment. Dedicated phenotype-specific trials and validated imaging biomarkers are needed to optimize management of stricturing CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag079","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:44:53Z","timestamp":1776944693000},"page":"1898-1909","source":"Crossref","is-referenced-by-count":0,"title":["The missing evidence: Stricturing Crohn\u2019s disease in clinical trials, a systematic review"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-7684","authenticated-orcid":false,"given":"Elettra","family":"Merola","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy , University of Sassari, Sassari 07100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0345-6171","authenticated-orcid":false,"given":"Daniele","family":"La Rocca","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy , University of Sassari, Sassari 07100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-8064","authenticated-orcid":false,"given":"Mariano","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy , University of Sassari, Sassari 07100,","place":["Italy"]},{"name":"Department of Radiology, James Cook University Hospital, Teesside University , Middlesbrough TS4 3BW,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-2823","authenticated-orcid":false,"given":"Giovanni Mario","family":"Pes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy , University of Sassari, Sassari 07100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-3531","authenticated-orcid":false,"given":"Maria Pina","family":"Dore","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy , University of Sassari, Sassari 07100,","place":["Italy"]},{"name":"Department of Medicine, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026093014401507300_izag079-B1","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19(Suppl A)","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol."},{"key":"2026093014401507300_izag079-B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2026093014401507300_izag079-B3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment","volume":"18","author":"Adamina","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/2050640620901960","article-title":"Natural history, diagnosis and treatment approach to fibrostenosing Crohn\u2019s disease","volume":"8","author":"El Ouali","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2026093014401507300_izag079-B5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/bjs.1800760407","article-title":"Ten-year experience of strictureplasty for obstructive Crohn\u2019s disease","volume":"76","author":"Dehn","year":"1989","journal-title":"Br J Surg"},{"key":"2026093014401507300_izag079-B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.crohns.2009.09.009","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: special situations","volume":"4","author":"Van Assche","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/ecco-jcc\/jjv080","article-title":"Bowel damage as assessed by the L\u00e9mann index is reversible on anti-TNF therapy for Crohn\u2019s disease","volume":"9","author":"Fiorino","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/s0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial","volume":"116","author":"D\u2019Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"2026093014401507300_izag079-B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2036.2008.03887.x","article-title":"Infliximab treatment for symptomatic Crohn\u2019s disease strictures","volume":"29","author":"Pelletier","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014401507300_izag079-B10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1365-2036.2012.05100.x","article-title":"Efficacy and safety of infliximab and adalimumab in Crohn\u2019s disease: a single centre study","volume":"35","author":"Zorzi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014401507300_izag079-B12","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf023","article-title":"Assessment of activity and severity of inflammatory bowel disease in cross-sectional imaging techniques: a systematic review","volume":"19","author":"Dal Buono","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026093014401507300_izag079-B14","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.26633\/RPSP.2022.112","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas]","volume":"46","author":"Page","year":"2022","journal-title":"Rev Panam Salud Publica."},{"key":"2026093014401507300_izag079-B15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"2026093014401507300_izag079-B16","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"2026093014401507300_izag079-B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"2026093014401507300_izag079-B18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2468-1253(21)00393-9","article-title":"Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn\u2019s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial","volume":"7","author":"Schulberg","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026093014401507300_izag079-B19","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/ibd\/izaf073","article-title":"Crohn\u2019s disease stricture response to treatment assessed with magnetic resonance imaging and intestinal ultrasound: STRIDENT randomized trial","volume":"31","author":"Lovett","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014401507300_izag079-B20","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izag0122026","article-title":"Stricture dynamics and prognosis during biologic therapy in ileal Crohn\u2019s disease: a real-world cohort","author":"Takenaka","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014401507300_izag079-B21","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/ecco-jcc\/jjab045","article-title":"Outcomes of passable and non-passable strictures in clinical trials of Crohn\u2019s disease: a post-hoc analysis","volume":"15","author":"Narula","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3748\/wjg.14.1885","article-title":"Effect of infliximab on small bowel stenoses in patients with Crohn\u2019s disease","volume":"14","author":"Pallotta","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2026093014401507300_izag079-B23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.5152\/tjg.2023.22768","article-title":"Serial changes in intestinal stenotic stiffness in patients with Crohn\u2019s disease treated with biologics: a pilot study using ultrasound shear wave elastography","volume":"34","author":"Matsumoto","year":"2023","journal-title":"Turk J Gastroenterol"},{"key":"2026093014401507300_izag079-B24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026093014401507300_izag079-B25","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026093014401507300_izag079-B26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"2026093014401507300_izag079-B27","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.crohns.2014.09.005","article-title":"A prospective 52 week mucosal healing assessment of small bowel Crohn\u2019s disease as detected by capsule endoscopy","volume":"8","author":"Hall","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B28","first-page":"15","article-title":"Treatment of small bowel subocclusive Crohn\u2019s disease with infliximab: an open pilot study","volume":"70","author":"Louis","year":"2007","journal-title":"Acta Gastroenterol Belg"},{"key":"2026093014401507300_izag079-B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-2003-36677","article-title":"[Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn\u2019s disease]","volume":"41","author":"Holtmann","year":"2003","journal-title":"Z Gastroenterol"},{"key":"2026093014401507300_izag079-B30","doi-asserted-by":"crossref","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: part 1","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B31","doi-asserted-by":"crossref","first-page":"jjaf107","DOI":"10.1093\/ecco-jcc\/jjaf107","article-title":"ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: part 2","volume":"19","author":"Yanai","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093014401507300_izag079-B32","doi-asserted-by":"publisher","author":"Merola","year":"2026","DOI":"10.1093\/ecco-jcc\/jjaf231.558"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/1898\/68282248\/izag079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/1898\/68282248\/izag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:40:25Z","timestamp":1790793625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/10\/1898\/8677808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag079","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,14]]}}}